首页> 美国卫生研究院文献>Medical Journal of the Islamic Republic of Iran >Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis
【2h】

Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis

机译:柠檬酸他洛尔定是否是一种有效且具有成本效益的血液透析导管锁定解决方案?系统审查和成本效益分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Prevention of catheter-related infection is of prime importance,. However, because of the risks caused by the leakage of circulating antibiotics and development of resistance to antibiotics, they are replaced by lock solutions. The aim of this study was to evaluate the efficacy and cost- effectiveness of taurolidine-citrate as a hemodialysis catheter lock solution compared to other common alternatives in Iran. >Methods: To evaluate the efficacy of taurolidine-citrate, a systematic review was conducted by searching electronic databases. The outcomes of interest for cost-effectiveness analysis were as follows: "Catheter-related bacteremia episodes"; "catheter-related bacteremia-free survival"; "catheter thrombosis rate" for efficacy evaluation and "reduction of catheter-related infection". For evidence synthesis, a meta-analysis was conducted on the extracted efficacy data. To evaluate the cost of treatments, direct medical costs were included, and the incremental cost-effectiveness ratio was calculated for each comparison. The payers’ (patients and insurance companies) perspectives were used for cost analysis. >Results: After carrying out the systematic process, three articles were included in the analysis. Considering95% confidence interval, the relative difference was -0.16 (-0.25 to -0.07) for catheterrelatedbacteremia episode, indicating that the rate of catheter-related infections in hemodialysis patientswho used taurolidine-citrate was 16% less than in those hemodialysis patients who receivedheparin. Considering 95% confidence interval, the relative difference was 0.13 (-0.06 0.32) for catheterthrombosis, showing that the rate of catheter-related thrombosis in hemodialysis patients whoused taurolidine-citrate was 13% more than in hemodialysis patients who received heparin. The resultsof this analysis indicated that taurolidine-citrate, compared to heparin, was more effective inpreventing catheter-related infection; therefore, it could be considered as a superior strategy. Nevertheless,compared to heparin-gentamicin combination, taurolidine-citrate is an inferior strategy becauseof its higher cost and lower infection prevention.>Conclusion: Compared to heparin, taurolidine-citrate is a superior option, but it is an inferior strategycompared to heparin-gentamicin combination. The clinical evidences on taurolidine-citrate, heparinand gentamicin/heparin are not sufficient for making confident decisions.
机译:>背景:预防与导管相关的感染至关重要。但是,由于循环抗生素泄漏和对抗生素产生抗药性所带来的风险,因此将其替换为锁定溶液。这项研究的目的是评估与伊朗其他常见替代品相比,牛磺酸替罗洛定柠檬酸盐作为血液透析导管锁定溶液的功效和成本效益。 >方法:为了评估柠檬酸牛磺洛定的疗效,通过搜索电子数据库进行了系统的评价。成本效益分析感兴趣的结果如下:“导管相关菌血症发作”; “与导管有关的无细菌血症的存活率”; “导管血栓形成率”用于疗效评估和“减少导管相关感染”。为了进行证据综合,对提取的功效数据进行了荟萃分析。为了评估治疗费用,包括了直接医疗费用,并为每个比较计算了增量成本效益比。付款人(患者和保险公司)的观点用于成本分析。 >结果:在进行了系统的过程之后,分析中包含了三篇文章。考虑中置信区间为95%,与导管相关的相对差异为-0.16(-0.25至-0.07)菌血症发作,表明血液透析患者的导管相关感染率谁使用柠檬酸牛磺洛定比那些接受血液透析的患者减少了16%肝素。考虑95%的置信区间,导管的相对差异为0.13(-0.06 0.32)血栓形成,表明血液透析患者中​​与导管相关的血栓形成发生率所用的他洛尔定柠檬酸盐比接受肝素的血液透析患者多13%。结果分析的结果表明,与肝素相比,牛磺酸牛磺酸牛磺酸更有效预防导管相关感染;因此,它可以被视为一种高级策略。不过,与肝素-庆大霉素联合用药相比,牛磺酸替瑞罗定是次等策略,因为其较高的成本和较低的感染预防。>结论:与肝素相比,牛磺酸牛磺酸牛黄素是一种更好的选择,但它是一种劣等策略与肝素-庆大霉素组合相比。柠檬酸牛磺罗定,肝素的临床证据和庆大霉素/肝素不足以做出自信的决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号